Sun Pharma Advanced Research Co

Sun Pharma Advanced Research Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Sun Pharma Advanced Research Co (SPARC.NS) as of Oct 10, 2026 is -19.11 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 108.21 % — a change of -117.66% (lower).

FCF Conversion

-19.11 %

YoY

-117.66%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Sun Pharma Advanced Research Co is 2026 -19.11 % . FCF Conversion Rate (FCF/EBITDA) of Sun Pharma Advanced Research Co was 2025 108.21 % . It decreases by -117.66% lower compared to the previous year.

The Sun Pharma Advanced Research Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
127.12 INR
Jan 1, 2020
84.78 INR
Jan 1, 2021
104.47 INR
Jan 1, 2022
118.44 INR
Jan 1, 2023
37.97 INR
Jan 1, 2024
117.69 INR
Jan 1, 2025
108.21 INR
Jan 1, 2026
-19.11 INR
The Sun Pharma Advanced Research Co FCF Conversion history
YEARFCF ConversionYoY
-19.11 %-117.66%
108.21 %-8.05%
117.69 %+209.96%
37.97 %-67.94%
118.44 %+13.38%
104.47 %+23.23%
84.78 %-33.31%
127.12 %+16.25%
109.34 %-3.74%
113.59 %+40.62%
80.78 %-33.03%
120.62 %+10.10%
109.55 %—
Access this data via the Eulerpool API
Get Free API Key

Sun Pharma Advanced Research Co Stock analysis

What does Sun Pharma Advanced Research Co do? Sun Pharma Advanced Research Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sun Pharma Advanced Research Co stock

FCF Conversion Rate (FCF/EBITDA) of Sun Pharma Advanced Research Co is -19.11 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Sun Pharma Advanced Research Co changed from 108.21 % to -19.11 %, representing a -117.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Sun Pharma Advanced Research Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Sun Pharma Advanced Research Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API
Get Free API Key

Cash Flow — Sun Pharma Advanced Research Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Sun Pharma Advanced Research Co